The fragility of the U.S. vaccine supply

New England Journal of Medicine

Volumn 351, Issue 23, 2004, Pages 2443-2447

  Sloan, Frank A ^a   Berman, Stephen ^b   Rosenbaum, Sara ^c   Chalk, Rosemary A ^d   Giffin, Robert B ^d  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL ACADEMIES OF SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; VACCINE;

COST CONTROL; DISEASE MANAGEMENT; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE TYPE B; HOSPITAL PURCHASING; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; REVIEW; VACCINATION; ADULT; ARTICLE; CHILD; COST; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH INSURANCE; INSURANCE; LEGAL ASPECT; LEGAL LIABILITY; QUALITY CONTROL; STANDARD; UNITED STATES;

ADULT; CHILD; COSTS AND COST ANALYSIS; DRUG INDUSTRY; FINANCING, GOVERNMENT; HEALTH CARE REFORM; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; LIABILITY, LEGAL; QUALITY CONTROL; UNITED STATES; VACCINES;

EID: 16544363332     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsb033394     Document Type: Review

References (25)

1. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:664-6.
2. Influenza and pneumococcal vaccination levels among persons aged > or = 65 years - United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:1019-24.
3. Institute of Medicine. Financing vaccines in the 21st century: assuring access and availability. Washington, D.C.: National Academies Press, 2003.
4. Sing M, Willam MK. Supplying vaccines: an overview of the market and regulatory context In: Pauly M, Robinson CA, Sepe S, Sing M, Willian MK, eds. Supplying vaccine: an economic analysis of critical issues. Amsterdam: IOS Press, 1996:45-99.
5. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep 2004;53:177-8.
6. Foulkes MA, Ellenberg SS. Vaccine efficacy and safety evaluation. In: The Jordan report: accelerated development of vaccines 2002. Bethesda, Md.: National Institutes of Allergy and Infectious Diseases, 2002:50-6.
7. Carpenter DP. The political economy of FDA drug review: processing, politics, and lessons for policy. Health Aff (Millwood) 2004;23(1):52-63.
8. Wiktorowicz ME. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France. J Health Polit Policy Law 2003;28:615-58.
9. Grabowski HG, Vernon JM. The search for new vaccines: the effects of the Vaccines for Children Program. Washington, D.C.: AEI Press, 1997.
10. Kremer M, Snyder CM. Why are drugs more profitable than vaccines? Working paper no. W9833. Cambridge, Mass.: National Bureau of Economic Research, July 2003.
11. Holahan J, Wang M. Changes in health care coverage 2000-2001. Washington, D.C.: Henry J. Kaiser Family Foundation, March 2003.
12. Fontanesi J, De Guire M, Holcomb K, Sawyer MH. The cost to immunize during well-child visits. Am J Med Qual 2001;16:196-201.
13. Glazner JE, Steiner JF, Haas KJ, Renfrew B, Deutchman M, Berman S. Is reimbursement for childhood immunizations adequate? Evidence from two rural areas in Colorado. Public Health Rep 2001;116:219-25.
14. Freed GL, Davis MM, Andreae MC, Bass S, Weinblatt H. Reimbursement for Prevnar: a modern-day version of Hercules and the Hydra. Pediatrics 2003;2:399-400.
15. Zimmerman RK, Medsger AR, Ricci EM, Raymund M, Mieczkowski TA, Grufferman S. Impact of free vaccine and insurance status on physician referral of children to public vaccine clinics. JAMA 1997;278:996-1000.
16. Lieu TA, Smith MD, Newacheck PW, Langthorn D, Venkatesh P, Herradora R. Health insurance and preventive care sources of children at public immunization clinics. Pediatrics 1994;93:373-8.
17. Childhood vaccines: ensuring an adequate supply poses continuing challenges. Washington, D.C.: General Accounting Office, September 2002. (GAO-02-987.)
18. Santoli JM, Peter G, Arvin AM, et al. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA 2003;290:3122-8.
19. Finkelstein A. Static and dynamic effects of health policy: evidence from the vaccine industry. QJ Econ 2004;119:527-64.
20. McGuire TG. Setting prices for new vaccines (in advance). Int J Health Care Finance Econ 2003;3:207-24.
21. Sloan FA, ed. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995.
22. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of the use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000;154:797-803.
23. Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev Med 2001;33:639-45.
24. Hinman AR, Gellin BG, National Vaccine Advisory Committee. Institute of Medicine report on financing vaccines in the 21st century: National Vaccine Advisory Committee/National Vaccine Program Office follow-up. (Accessed November 10, 2004, at http://www.hhs.gov/nvpo/nvac/NVAC-IOM100604.htm.)
25. Orenstein W. Protecting our kids: what is causing the current shortage in childhood vaccines? Hearing before the Senate Committee on Governmental Affairs (June 6). Washington, D.C.: Government Printing Office, 2002.